Most Read Articles
4 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
5 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Hormone combination helps short teens become taller

17 Sep 2020

In teens with short stature, the combination of gonadotropin releasing hormone analogue (GnRHa) and recombinant human growth hormone (rhGH) yields a significant increase in adult height, as shown in a study.

A total of 94 adolescents with normal pubertal onset and short stature were treated with GnRHa/rhGH: 49 boys for a mean of 24.84 months and 45 girls for a mean of 23.89 months. Among them, 25 boys and 12 girls had idiopathic short stature (ISS). All participants were followed to measure their adult height.

At baseline, in boys, the height (Ht) standard deviation score (SDS) was −1.82, while the target height was 168.98 cm. In girls, the HtSDS was −1.10, and the target height was 157.90 cm. After treatment, adult height SDS increased by 1.37 (p=0.000) in boys and by 1.28 (p=0.000) in girls.

The adult height in boys was 169.96 cm, taller by 0.98 cm than the target height (p=0.273). Girls, on the other hand, gained more. Their adult height was 161.54 cm, which was 3.64-cm greater than their target height (p=0.000).

Subgroup analysis revealed that teens with ISS were able to reach their target height. In boys, although their adult height was 0.70-cm short of the target, the SDS value indicated that adult height increased by 2.00 relative to pre-treatment HtSDS (p=0.000). In girls, their adult height was greater by 2.63 cm than the target, with the SDS increasing by 2.73 vs HtSDS (p=0.000).

On the other hand, teens without ISS achieved a height that exceeded their targets. Compared with the target, adult height increased by 2.73 cm in boys and 4.02 cm in girls. The differences between adult height SDS and HtSDS were 0.71 (p=0.003) and 0.748 (p=0.001), respectively.

In multiple linear regression analysis, significant factors that negatively influenced adult height SDS increments were baseline bone age (p=0.003), basal IGF-1 (p=0.008), and HtSDS (p=0.000).

There were no serious adverse reactions reported. One child reported a transient mild headache, and two had a small rash and mild itching at the injection site. None of these symptoms resulted in treatment interruption or withdrawal. There were no incidences of bone fracture.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
5 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.